Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Posts Tagged ‘disease’

5a edizione di “Uno Sguardo Raro”: the Rare Disease International Film Festival

Posted by fidest press agency su mercoledì, 10 luglio 2019

È online sul sito di “Uno sguardo Raro” (www.unosguardoraro.org) il bando per partecipare alla 5a edizione di “Uno Sguardo Raro” – the Rare Disease International Film Festival, il festival di cinema internazionale sul tema delle malattie rare 2020.
L’iscrizione è gratuita e aperta a tutti. Il 30 novembre 2019 è la scadenza entro la quale sarà possibile caricare le opere sulla piattaforma FilmFreeway (https://bit.ly/2ltPIMv). Nato per raccontare cosa significhi vivere con una malattia rara o con abilità diverse e per stimolare, attraverso la narrazione cinematografica, una riflessione su come sia possibile affrontare questi temi con registri di comunicazione innovativi e ad alto impatto emotivo, il Festival rappresenta la sfida – raccolta da giovani filmaker di tutto il mondo, da malati rari, da associazioni pazienti e da chi vive con loro – di raccontare questa realtà da un punto di vista diverso, con “Uno Sguardo Raro”. L’appuntamento con il Festival è a Roma dal 9 al 15 marzo 2020, in diverse sedi.
Come sempre, uno degli obiettivi più importanti di Uno Sguardo Raro è quello di coinvolgere sempre più giovani, studenti universitari e allievi delle scuole di cinema, arte e comunicazione, per interessare le nuove generazioni al tema delle malattie rare con l’auspicio che queste possano non solo raccontarlo al pubblico attraverso il proprio lavoro, ma stimolare anche una maggiore inclusione sociale per questa comunità.
Saranno selezionate le migliori opere video sul tema delle malattie rare, video di sensibilizzazione e sull’importanza dell’inclusione sociale, ma anche opere che parlano di disabilità, empatia, resilienza, o della capacità di superare i propri limiti, questo per celebrare le qualità che le persone con limitazioni di qualunque tipo mettono in campo per vivere appieno la loro vita. Uno Sguardo raro vuole creare un punto d’incontro solidale tra il mondo del cinema e questa realtà ricca di spunti narrativi intensi ed emozionanti con la speranza di aumentare la consapevolezza dell’opinione pubblica su questi temi e sull’impatto che le malattie rare e la disabilità hanno sulla vita quotidiana delle famiglie. I lavori saranno giudicati e premiati una Giuria di Qualità composta da professionisti del cinema, della comunicazione, del mondo scientifico e della comunità dei rari. A questi viene affiancata anche una Menzione Speciale Giuria Popolare decretata dalle votazioni del pubblico.
Uno Sguardo Raro è felice di annunciare che quest’anno i vincitori riceveranno un premio di € 500,00 per 4 categorie in concorso: Miglior Cortometraggio Italiano, Miglior Cortometraggio Internazionale, Miglior Corto di Animazione, Miglior Documentario. In tema di novità, quest’anno il Premio Comunicazione realizzato con FERPI entra ufficialmente nelle categorie in concorso ed è aperto sia ad Associazioni Pazienti che ad Aziende Farmaceutiche che possono presentare video di sensibilizzazione o che incoraggino un cambiamento di comportamento. Anche il Corto/Spot di Comunicazione in Sanità e relativa campagna social in collaborazione con PA SOCIAL è parte delle categorie in concorso ed è aperto a Ospedali, ASL, Associazioni pazienti che operano in ospedale che possono partecipare con prodotti video di servizio rivolti sia al pubblico che al personale interno. Questa è una novità assoluta per il nostro Festival.
Conferma per il Premio HEYOKA, un fuori concorso nato dall’incontro di Uno Sguardo Raro con la Community di Heyoka Empath, progetto di Ability Channel, storica testata on line dedicata alla disabilità “positiva”. Heyoka Empath stimola le persone a “Spezzare le catene, andare oltre i propri limiti, essere d’esempio”. Tra tutte le opere ricevute da Uno Sguardo Raro, la giuria del Premio HEYOKA selezionerà opere che rispondono al tema dell’empatia e dell’inclusione e le farà votare dalla propria community.
Uno Sguardo Raro (www.unosguardoraro.org) nasce dall’incontro di Claudia Crisafio, autrice e attrice, e Serena Bartezzati, malata rara e professionista della comunicazione.
Si definisce RARA una malattia che colpisce meno di 5 persone su 10.000. Le patologie rarissime ne colpiscono meno di una su un milione. Ma sono rare le malattie, non i pazienti. Infatti, secondo la rete Orphanet, i malati sarebbero oltre il milione e mezzo in Italia e EURORDIS, la rete delle alleanze europee delle MR, stima in 30 milioni i pazienti in EUROPA. Per capire la portata del problema per le nuove generazioni, secondo il rapporto MonitoRare della Federazione UNIAMO, 1 paziente su 5 è al di sotto dei 18 anni. Stiamo parlando di una comunità a cui è importante dare voce come è importante far circolare le esperienze anche di paesi e culture diverse per vedere le cose con altre prospettive e far crescere una nuova sensibilità, ed è questo uno degli obiettivi del Festival.

Posted in Recensioni/Reviews | Contrassegnato da tag: , , , | Leave a Comment »

Treatment of patients with chronic obstructive pulmonary disease

Posted by fidest press agency su mercoledì, 3 aprile 2019

Almirall, S.A (ALM), announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Duaklirâ (aclidinium bromide/formoterol 400/12 mg, twice daily), for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Duaklir® offers a fixed-dose combination of a novel long-acting muscarinic antagonist (LAMA), aclidinium bromide and a fast long acting beta2-agonist (LABA), formoterol fumarate, administered through the GENUAIR® inhaler device.The FDA has approved Duaklir® based on the positive results of the AMPLIFY study, that shows Duaklir® significantly improved lung function in patients with moderate to severe COPD compared to each individual component (either aclidinium bromide or formoterol). The Phase III AMPLIFY study also proved that the efficacy, safety and tolerability profiles for aclidinium bromide and formoterol were consistent with current experience. In comparison to tiotropium bromide 18µg once-daily, both Duaklir® and aclidinium bromide monotherapy demonstrated significantly higher levels of bronchodilation during the night-time, whilst aclidinium bromide monotherapy showed non-inferior bronchodilation to tiotropium over 24 weeks. This approval by the FDA in the US means another positive step in the partnership of Almirall and AstraZeneca.In addition this is the third product discovered in the R&D Center of Almirall approved by the FDA.
The positive results of the Phase IV ASCENT trial for Tudorza® Pressair® (aclidinium bromide 400 μg, twice-daily) with 3.600 patients demonstrating a statistically significant reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo, has been translated in a relevant change in the Package Insert of this product in the US and also reflected in the current approval of Duaklir®.On 1st November 2014, Almirall entered an agreement to transfer the rights for the development and commercialisation of its respiratory franchise, as well as its pipeline of investigational novel therapies to AstraZeneca. This global collaboration included milestones associated to development, launch and future Duaklir® sales in US.Almirall could receive additional milestones and royalties, which have not been disclosed.Almirall remains positive about this partnership that has allowed to maximize the return and value of the company’s assets and capabilities.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease

Posted by fidest press agency su giovedì, 30 agosto 2018

Late-breaking data published and presented today confirm that the non-invasive HeartFlow® FFRct Analysis enables physicians to effectively differentiate patients in need of coronary stenting or bypass surgery from those who can be managed with medications alone.
The ADVANCE Registry was published in the European Heart Journal (EHJ) and the Aarhus University Hospital experience was published in the Journal of the American College of Cardiology (JACC). Both studies were presented during the late-breaking science session today at the European Society of Cardiology (ESC) conference.In these studies, the HeartFlow Analysis changed physician management of patients and enabled physicians to determine more efficiently which patients required invasive management and which did not. The HeartFlow Analysis identified a set of patients at very low risk of adverse outcomes when undergoing medical therapy, and a set whose risk was reduced when undergoing invasive management.
The ADVANCE Registry included more than 5,000 patients in the U.S., Japan, Europe and Canada. The Aarhus University Hospital experience included more than 3,600 patients in Denmark who were followed for an average of two years. “These studies confirm the role of the HeartFlow Analysis in identifying disease that other tests may miss, and in providing reassurance to patients and doctors that some blockages are not in need of invasive management,” said Campbell Rogers, MD, FACC, chief medical officer, HeartFlow.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

“Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment”

Posted by fidest press agency su mercoledì, 22 novembre 2017

stoccolmaStoccolma dal 01 al 03 dicembre 2017 “Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment”. Una circonferenza dell’addome sopra la media, colesterolo, glicemia e pressione del sangue oltre i livelli raccomandati: sono le caratteristiche del rischio metabolico, tra le principali cause di malattie cardiache e vascolari. Si tratta di una condizione che interessa circa il 25 per cento degli uomini ed addirittura il 27 per cento delle donne. Parliamo quindi di numeri altissimi, pari a circa 14 milioni di individui in Italia, ma che diventano ancora più impressionanti se pensiamo all’Europa, agli Stati Uniti, dove è obeso o in sovrappeso una persona su tre, e nel resto del mondo. E dato che lo studio della sindrome metabolica è una delle principali chiavi per migliorare a costo zero la prevenzione cardiovascolare, gli esperti europei si incontreranno a Stoccolma (Svezia) dall’1 al 3 dicembre 2017 in occasione del Simposio “Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment” organizzato dal Karolinska Institute di Stoccolma con il supporto della Fondazione Internazionale Menarini. «Gli obiettivi del simposio sono la condivisione delle più recenti conoscenze relative ai progressi nella fisiologia, nella diagnosi e nel trattamento del rischio cardiometabolico e il suo impatto nella pratica clinica» spiega Francesco Cosentino, Direttore dell’Unità di Cardiologia del Karolinska Institute & Karolinska University Hospital di Stoccolma. «Il programma scientifico copre uno spettro di temi tra cui la relazione tra sistema immunitario e metabolismo, tra infiammazione e aterosclerosi, le strategie di prevenzione delle patologie cardiovascolari, la gestione dell’obesità e dell’insulino-resistenza, il controllo dell’aterotrombosi, della glicemia, del diabete, della sindrome coronarica acuta e dello scompenso cardiaco.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Innovations to prevent heart disease take centre stage at EuroPrevent congress

Posted by fidest press agency su mercoledì, 8 marzo 2017

Sophia AntipolisSophia Antipolis. Innovations to prevent heart disease will take centre stage at EuroPrevent 2017 in Malaga, Spain.EuroPrevent is the annual congress of the European Association of Preventive Cardiology (EAPC), a registered branch of the European Society of Cardiology (ESC). EuroPrevent 2017 takes place 6 to 8 April at the Palacio de Ferias y Congresos de Malaga (FYCMA). This year’s theme is “innovations in preventive cardiology”. The congress will explore novel ideas and technologies that could have an impact on society and what that impact could mean. “It’s the right time to talk about innovation in preventive cardiology because we are moving beyond classical treatments and approaches on a number of fronts,” said Professor Jean-Paul Schmid, programme committee chair.
Could the Nordic diet be the new Mediterranean diet? Experts will discuss how it provides cardiovascular protection that is also eco-friendly. Sessions on nutrition will also explore diet and the microbiome as the next frontier in cardiovascular prevention, examine whether patients with metabolic syndrome should eat low carbohydrate or low cholesterol diets, and ask “Do superfoods exist and do we need them?”.“Nutrition used to be our main weapon to lower cholesterol but it took a back seat when statins came on the scene,” said Professor Schmid. “EuroPrevent will look at new therapeutic uses of food and nutrients and also the potential dangers of genetically modified food.”
A breakthrough in the management of high cholesterol could see some patients using monoclonal antibodies called PCSK9-inhibitors. Journalists will find out which patients should add these to their statin regime and how effective the newer drugs are. Novel oral antidiabetic drugs are another important discovery that will be presented.Professor Schmid said: “Monoclonal antibodies are used in oncology and rheumatology, and now intensive lipid lowering with this new class of drugs is a hot topic. This potent medication may help patients unable to reach cholesterol targets on statins alone and better protect patients with familial hypercholesterolaemia who have genetically high cholesterol. Leaders in the field will talk about the safety of very low lipid levels.”
A session on social inequalities will examine cardiovascular disease incidence and survival in migrants, and explain the association between cardiovascular risk factors and borough socioeconomic level. “Cardiovascular disease in migrants is an increasingly important topic and we need strategies for prevention,” said Professor Schmid. “Members of the press will hear about the scale of the problem, how these populations are unique, and how we might screen and then help them.”
The latest science on the health effects of e-cigarettes and waterpipe will be presented, along with the impact of TV and movies on tobacco use and cessation in the young. “After the harms of secondhand smoke were confirmed and actions taken to prevent it we thought we knew everything about tobacco,” said Professor Schmid. “But e-cigarettes have reactivated the discussion about smoking, smoking cessation, and smoking behaviour. We will delve into the latest facts about the hazards of e-cigarettes and waterpipe.”
Experts will present the most up-to-date evidence on physical activity monitoring in patients with cardiovascular disease and investigate whether mobile apps help prevent cardiovascular disease in people of all ages. Journalists will hear lively, balanced debates on whether too much exercise can be detrimental to cardiovascular health, and whether exercise restriction is necessary for athletes with cardiac disease.Dr Michael Joner, previous winner of an ESC Grant for Medical Research Innovation will give the EuroPrevent 2017 Keynote Lecture. The Spanish Society of Cardiology will hold cardiopulmonary resuscitation workshops for the general public at Malaga Town Hall on all three days of the congress.Professor Schmid said: “As the leading international congress in preventive cardiology, EuroPrevent covers epidemiology and population science, cardiac rehabilitation and exercise, and sports cardiology. We are expecting more than 1000 cardiologists, allied health professionals, general practitioners, researchers and policy makers to attend. Journalists should register now for this top notch event.”

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Cardiovascular Disease in the Elderly

Posted by fidest press agency su lunedì, 29 agosto 2016

cardiology congress-2016Rome, Italy Monitoring platelet function in order to individualize antiplatelet therapy did not improve outcomes for elderly patients after a heart attack compared to a standard, unmonitored approach, results of the ANTARCTIC trial show.The findings, presented in a Hot Line session at ESC Congress 2016, and with simultaneous publication in Lancet, challenge current international guidelines which recommend platelet function testing in high risk patients.“Platelet function testing is still being used in many centres to measure the effect of antiplatelet drugs and adjust the choice of these drugs and their doses. Our study does not support this practice and these recommendations,” said senior investigator Gilles Montalescot M.D, Ph.D, from Hôpital Pitié-Salpêtrière, in Paris, France.“Although measuring the effect of antiplatelet agents makes sense in order to choose the best drugs or doses, this costly and more complex strategy does not appear to benefit patients, even when they present with extremely high risk of ischemic and bleeding events liked those enrolled in ANTARCTIC.”
ANTARCTIC is the only study of platelet function testing in elderly patients at very high risk of ischemic and bleeding complications.It enrolled 877 patients, aged 75 years or more, who presented with an acute coronary syndrome and underwent coronary stenting.All patients were started on the antiplatelet agent prasugrel (5mg), with 442 randomised to the conventional therapy (no adjustment) and 435 to monitoring and treatment adjustment, if needed.Patients in the monitoring arm received 14 days of the daily 5mg prasugrel dose, but then underwent a platelet function test at Day 14, followed by medication adjustment, if the test showed high or low platelet reactivity. Additional monitoring was performed at Day 28 in patients who needed treatment adjustment.
The primary end point of the trial was the composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, urgent revascularization and bleeding complication at 1-year.This endpoint occurred at a similar rate in both arms of the study: 27.6% in the monitoring group, and 27.8% in the conventional group (hazard ratio [HR], 1.003; 95% confidence interval [CI], 0.78 to 1.29; P=0.98).There was similarly no significant difference in rates of the main secondary end point (a composite of cardiovascular death, myocardial infarction, stent thrombosis or urgent revascularization), which occurred in 9.9% and 9.3%, respectively (HR, 1.06; 95% CI, 0.69 to 1.62; P=0.80).“Platelet function monitoring led to a change of treatment in 44.8% of patients who were identified as being over- or under-treated, yet this strategy did not improve ischemic or safety outcomes,” noted Professor Montalescot.
“ANTARCTIC confirms the ARCTIC study (NEJM 2011) in a different population with a different drug, and has addressed the potential limitations of the ARCTIC study, but finally reached the same conclusion. I expect there will be adjustments of guidelines and practice in light of this.”ANTARCTIC stands for Assessment of a Normal versus Tailored dose of prasugrel after stenting in patients
Aged > 75 years to Reduce the Composite of bleeding, stent Thrombosis and Ischemic Complications).

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Low control for high cholesterol

Posted by fidest press agency su mercoledì, 2 febbraio 2011

The largest ever study – representing 147 million people – shows that most people with high cholesterol levels are not getting the treatment they need to reduce their risk of cardiovascular disease such as heart attack and stroke. Many of these people – living in England, Germany, Japan, Jordan, Mexico, Scotland, Thailand and the United States of America – are unaware that they need treatment, which is easily accessible in the form of low-cost medicines. This study, published today in the international public health journal, the Bulletin of the World Health Organization, is the first to show the extent of the treatment gap for high cholesterol – a common risk factor for early cardiovascular deaths. In Thailand, for example, 78% of adults surveyed had not been diagnosed, while in Japan, 53% of adults were diagnosed but remained untreated.
http://www.who.int/bulletin/volumes/89/02/10-079947.pdf
The Bulletin of the World Health Organization is one of the world’s leading public health journals. It is the flagship periodical of WHO, with a special focus on developing countries. Articles are peer-reviewed and are independent of WHO guidelines. Abstracts are now available in the six official languages of the United Nations. Further items in this month’s issue include:
•    What is the ideal weight gain during pregnancy? A study from Viet Nam
•    Modern contraceptive use in Africa stagnates
•    Radio programme helps combat food insecurity
•    Why so slow to develop new antibiotics?
•    Diabetes – a product of modern technology

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Alzheimer e prevenzione

Posted by fidest press agency su lunedì, 11 ottobre 2010

(Centro Maderna)  La Conferenza del National Institute on Aging sulla prevenzione della malattia di Alzheimer ha concluso che non esiste evidenza scientifica sulla possibilità di prevenire la malattia e le altre demenze. E’ possibile però fare qualcosa per mantenere corpo e cervello sano. “Can Alzheimer’s Disease Be Prevented?” (Si può prevenire la malattia di Alzheimer?) è il titolo dell’opuscolo on line sul sito di National Institute on Aging. L’opuscolo fornisce utili e sintetici consigli, oltre a informazioni scientifiche, sulla possibilità di prevenire l’insorgenza dell’Alzheimer attraverso un adeguato stile di vita.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »